ZyVersa Therapeutics Inc (NASDAQ: ZVSA)’s stock price has plunge by 6.88relation to previous closing price of 0.64. Nevertheless, the company has seen a -2.56% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-20 that Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein leading to neurodegeneration in Parkinson’s Disease (PD). Our data showed that microglial inflammation was driven by activation of NLRP1 inflammasomes triggered by ASC specks and alpha-synuclein aggregates.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
Company’s 36-month beta value is 0.74.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVSA is 4.76M, and currently, short sellers hold a 6.32% ratio of that floaft. The average trading volume of ZVSA on June 18, 2025 was 3.63M shares.
ZVSA’s Market Performance
ZVSA stock saw an increase of -2.56% in the past week, with a monthly gain of 30.81% and a quarterly increase of -9.95%. The volatility ratio for the week is 6.49%, and the volatility levels for the last 30 days are 5.52% for ZyVersa Therapeutics Inc (ZVSA). The simple moving average for the past 20 days is 7.90% for ZVSA’s stock, with a -46.53% simple moving average for the past 200 days.
ZVSA Trading at 4.17% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.14% of loss for the given period.
Stock Fundamentals for ZVSA
The total capital return value is set at -0.24. Equity return is now at value -91.39, with -41.48 for asset returns.
Currently, EBITDA for the company is -9.14 billion with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.18.
Conclusion
In a nutshell, ZyVersa Therapeutics Inc (ZVSA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
